Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
- Associated Therapies
- -
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT02015065
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02013089
- Locations
- 🇨🇳
Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- University College, London
- Registration Number
- NCT01941849
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, London, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Ronald Weigel
- Target Recruit Count
- 12
- Registration Number
- NCT01934335
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Vandetanib in Advanced NSCLC With RET Rearrangement
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT01823068
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 153
- Registration Number
- NCT01582191
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT01561781
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01544140
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT01539655
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT01414426
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.